GlassScriptPhysician profile
Taylor Selke
NPI 1033822119
$956.99
in general payments reported to CMS, 2019-2025
13 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $508 · 2024: $235 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.87 | 2023-2025 | |
| Axsome Therapeutics, INC. | $140.86 | 2023 | Sunosi |
| Janssen Pharmaceuticals, INC | $138.15 | 2023-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $116.39 | 2024 | |
| Supernus Pharmaceuticals, INC. | $88.36 | 2024-2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $84.96 | 2023 | Quviviq |
| Lilly USA, LLC | $34.97 | 2025 | Zepbound |
| Neurocrine Biosciences, INC. | $23.00 | 2025 | |
| Sage Therapeutics, LLC | $20.50 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $19.96 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $17.80 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.69 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $16.48 | 2024 | Rexulti, Abilify Maintena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Selke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.